TD Cowen lowered the firm’s price target on Biote (BTMD) to $6 from $8 and keeps a Buy rating on the shares. The firm said with the new CEO ...

biote Corp. , which belongs to the Zacks Medical - Products industry, posted revenues of $49.83 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.85%.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic ...

And that really is a reflection of the product offering. And as I think about the value of Biote, we've got fantastic products. So we've got testosterone pellets, we've got the B-glycemic balls ...

“In 2024 Biote strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote Chief Financial Officer. “Full year 2024 ...